GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » InnovAge Holding Corp (NAS:INNV) » Definitions » Altman Z2-Score

InnovAge Holding (InnovAge Holding) Altman Z2-Score : 0.96 (As of May. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is InnovAge Holding Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

InnovAge Holding has a Altman Z2-Score of 0.96, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for InnovAge Holding's Altman Z2-Score or its related term are showing as below:

INNV' s Altman Z2-Score Range Over the Past 10 Years
Min: 0.84   Med: 2.21   Max: 4.73
Current: 0.96

During the past 5 years, InnovAge Holding's highest Altman Z2-Score was 4.73. The lowest was 0.84. And the median was 2.21.


InnovAge Holding Altman Z2-Score Historical Data

The historical data trend for InnovAge Holding's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnovAge Holding Altman Z2-Score Chart

InnovAge Holding Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Altman Z2-Score
- 2.86 3.98 3.30 1.21

InnovAge Holding Quarterly Data
Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.48 1.21 1.14 1.00 0.96

Competitive Comparison of InnovAge Holding's Altman Z2-Score

For the Medical Care Facilities subindustry, InnovAge Holding's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnovAge Holding's Altman Z2-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, InnovAge Holding's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where InnovAge Holding's Altman Z2-Score falls into.



InnovAge Holding Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

InnovAge Holding's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.059+3.26*-0.1054+6.72*-0.0558+1.05*1.2276
=0.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was $527.4 Mil.
Total Current Assets was $153.1 Mil.
Total Current Liabilities was $122.0 Mil.
Retained Earnings was $-55.6 Mil.
Pre-Tax Income was -6.408 + -3.728 + -10.736 + -11.489 = $-32.4 Mil.
Interest Expense was -1.022 + -0.935 + -0.661 + -0.291 = $-2.9 Mil.
Total Liabilities was $229.0 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(153.066 - 121.973)/527.355
=0.059

X2=Retained Earnings/Total Assets
=-55.582/527.355
=-0.1054

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-32.361 - -2.909)/527.355
=-0.0558

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(281.15 - 0)/229.033
=1.2276

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

InnovAge Holding has a Altman Z2-Score of 0.96 indicating it is in Distress Zones.


InnovAge Holding  (NAS:INNV) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


InnovAge Holding Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of InnovAge Holding's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


InnovAge Holding (InnovAge Holding) Business Description

Traded in Other Exchanges
N/A
Address
8950 East Lowry Boulevard, Denver, CO, USA, 80230
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.
Executives
Teresa Sparks director 40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Nicole Damato officer: CHIEF LEGAL OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Benjamin C Adams officer: CHIEF FINANCIAL OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Patricia Fontneau director 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Christine Bent officer: CHIEF OPERATIONS OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Thomas Scully director 320 PARK AVENUE, SUITE # 2500, NEW YORK NM 10022
Richard Feifer officer: CHIEF MEDICAL OFFICER C/O GENESIS HEALTHCARE, INC., 101 EAST STATE STREET, KENNETT SQUARE PA 19348
James G Carlson director 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Patrick T Blair officer: PRESIDENT 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Caroline Dechert director 580 CALIFORNIA ST., SUITE 1700, SAN FRANCISCO CA 94104
Pavithra Mahesh director 601 LEXINGTON AVE., 53RD FLOOR, NEW YORK NY 10022
Maureen Hewitt director, officer: CEO, President and Director 8950 E. LOWRY BLVD., DENVER CO 80230
Maria Lozzano officer: CORPORATE COO 8950 E. LOWRY BLVD., DENVER CO 80230
Robin Doerr officer: CHIEF SALES AND MKTG. OFFICER 8950 E. LOWRY BLVD., DENVER CO 80230
Melissa Welch officer: CHIEF MEDICAL OFFICER 8950 E. LOWRY BLVD., DENVER CO 80230